Tags

Type your tag names separated by a space and hit enter

Metal-based antitumor compounds: beyond cisplatin.
Future Med Chem. 2019 01; 11(2):119-135.FM

Abstract

Despite improvements in the 5-year survival rate to over 80% in cancers, such as Hodgkin lymphoma and testicular cancer, more aggressive tumors including pancreatic and brain cancer still have extremely low survival rates. The establishment of chemoresistance, responsible for the reduction in treatment efficiency and cancer relapse, is one possible explanation for this setback. Metal-based compounds, a class of anticancer drugs, are largely used in the treatment of cancer. Herein, we will review the use of metal-based small molecules in chemotherapy, focusing on recent studies, and we will discuss how new nonplatinum-based agents are prompting scientists to increase drug specificity to overcome chemoresistance in cancer cells.

Authors+Show Affiliations

Department of Chemistry, Curtin Institute of Functional Molecules & Interfaces, Curtin University, Kent Street, Bentley, Western Australia 6102, Australia.Metabolic Signalling Group, School of Pharmacy & Biomedical Sciences, Curtin Health Innovation Research Institute, Curtin University, Perth, Western Australia 6102, Australia.Metabolic Signalling Group, School of Pharmacy & Biomedical Sciences, Curtin Health Innovation Research Institute, Curtin University, Perth, Western Australia 6102, Australia.Department of Chemistry, Curtin Institute of Functional Molecules & Interfaces, Curtin University, Kent Street, Bentley, Western Australia 6102, Australia.Metabolic Signalling Group, School of Pharmacy & Biomedical Sciences, Curtin Health Innovation Research Institute, Curtin University, Perth, Western Australia 6102, Australia.

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't
Review

Language

eng

PubMed ID

30644327

Citation

Simpson, Peter V., et al. "Metal-based Antitumor Compounds: Beyond Cisplatin." Future Medicinal Chemistry, vol. 11, no. 2, 2019, pp. 119-135.
Simpson PV, Desai NM, Casari I, et al. Metal-based antitumor compounds: beyond cisplatin. Future Med Chem. 2019;11(2):119-135.
Simpson, P. V., Desai, N. M., Casari, I., Massi, M., & Falasca, M. (2019). Metal-based antitumor compounds: beyond cisplatin. Future Medicinal Chemistry, 11(2), 119-135. https://doi.org/10.4155/fmc-2018-0248
Simpson PV, et al. Metal-based Antitumor Compounds: Beyond Cisplatin. Future Med Chem. 2019;11(2):119-135. PubMed PMID: 30644327.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Metal-based antitumor compounds: beyond cisplatin. AU - Simpson,Peter V, AU - Desai,Nima Maheshkumar, AU - Casari,Ilaria, AU - Massi,Massimiliano, AU - Falasca,Marco, Y1 - 2019/01/15/ PY - 2019/1/16/pubmed PY - 2019/8/9/medline PY - 2019/1/16/entrez KW - cancer KW - chemoresistance KW - chemotherapy KW - cisplatin KW - metal-based anticancer agents SP - 119 EP - 135 JF - Future medicinal chemistry JO - Future Med Chem VL - 11 IS - 2 N2 - Despite improvements in the 5-year survival rate to over 80% in cancers, such as Hodgkin lymphoma and testicular cancer, more aggressive tumors including pancreatic and brain cancer still have extremely low survival rates. The establishment of chemoresistance, responsible for the reduction in treatment efficiency and cancer relapse, is one possible explanation for this setback. Metal-based compounds, a class of anticancer drugs, are largely used in the treatment of cancer. Herein, we will review the use of metal-based small molecules in chemotherapy, focusing on recent studies, and we will discuss how new nonplatinum-based agents are prompting scientists to increase drug specificity to overcome chemoresistance in cancer cells. SN - 1756-8927 UR - https://www.unboundmedicine.com/medline/citation/30644327/Metal_based_antitumor_compounds:_beyond_cisplatin_ L2 - https://www.future-science.com/doi/full/10.4155/fmc-2018-0248?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub=pubmed DB - PRIME DP - Unbound Medicine ER -